Get started
Adial Pharmaceuticals, IncAdial Pharmaceuticals, IncAdial Pharmaceuticals, Inc

Adial Pharmaceuticals, Inc

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

ADIL trade ideas

ADIL - Low Conviction; High Upside Screener brought to my attention, volume looks great, and to me, the chart looks primed for a bounce. I dug into the fundamentals and they seem solid. On the charts, looks like we're forming an ascending triangle and it is now at the bottom of the trend line. The price from the bottom back in Feb bounced hard when they got a patent for awarded for potential to treat opiod us disorder. On this news, the price ran 445% in 4 days to form a pole for the bullish flag. Super Strong. Price action then trended down and bounced again with an EP of 106%. Super strong again. All the moving averages are converging and there just dropped some big news that they got a new patent in April for the alcohol disorder as well. There has been some massive volume that leaves the traces. On the 3 days back in Feb when the price ran for 445%, there was a total of 218 million in volume. On the 3 days prior to that, there was a total of 337 thousand in volume. That is a 646x increase. Some days back in January had 8k in daily volume and this news led to 111 million in a daily candle. This is still only a 2.8 million dollar company and I think this is a potential monster gainer. Earning are today and I think we could be in for a big bounce.
NASDAQ:ADILLong
by bettingbillions
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) Surges by 88%In a groundbreaking development, Adial Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ADIL ) has unveiled promising findings in the treatment of Alcohol Use Disorder (AUD) with its lead investigational drug, AD04 (low-dose ondansetron). A recently published peer-reviewed article showcases the remarkable clinical results, robust safety profile, and exceptional patient compliance observed during the trials. The study, featured in the European Journal of Internal Medicine, delves into the comprehensive analysis of AD04's liver safety profile compared to a placebo in individuals with AUD and a specific genetic profile. With AUD posing significant health risks and contributing to alcohol-associated liver disease (ALD), the need for effective treatments is paramount. Remarkably, low-dose AD04 demonstrated minimal impact on liver injury markers, such as ALT, AST, and Serum Bilirubin, compared to placebo. Notably, the treatment did not adversely affect GGT levels, a key indicator of alcohol consumption, further underscoring its safety and tolerability. The study also highlighted AD04's outstanding safety profile, with a low occurrence of adverse events and high medication compliance, a rarity in alcohol treatment literature. Cary Claiborne, CEO of Adial, hailed the publication as a significant milestone in addressing the critical needs of individuals suffering from AUD and ALD. He emphasized AD04's potential to revolutionize AUD treatment by offering a precision medication tailored to individuals with a specified genetic background. With AD04 paving the way for precision treatments, tailored interventions for AUD patients could soon become a reality. This groundbreaking advancement not only promises to curb alcohol consumption but also holds the potential to mitigate liver damage in affected populations, offering hope to millions worldwide. Technical Outlook Adial Pharmaceuticals, Inc. ( NASDAQ:ADIL ) stock is trading above the respective Moving Averages (MA) with a Relative Strength Index (RSI) of 65.30 indicating room for continuous growth.
NASDAQ:ADILLong
by DEXWireNews
ADIL - Retrace To Support - Good Entry?ADIAL saw an increase in volume and runup to 3.30 after which we saw a retrace to the 2.18 support level that held nicely. The upward trendline has been holding consistently on the daily and weekly charts. I am looking for a bullish engulfing or gap up opening with retrace to higher low to confirm the breakout continuation to test resistance at 2.82. If we can break through the 2.82 resistance level, I am looking for a price target of 3.30.
NASDAQ:ADILLong
by lwlagrange
3
$ADIL is gonna to fall todayPupm&Dump trading strategy idea. $ADIL is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,10; stop-loss — $2,35. take-profit — $1,85. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:ADILShort
by KozakHlib
Insider confidence in Adial Pharmaceuticals bodes wellAs Adial Pharmaceuticals advances its Phase 3 clinical trial of AD04 for the treatment of alcohol use, insiders are showing confidence in the company. Today they appointed Mark Howard Peikin as chief strategy officer, and he took the position without a salary. Instead, he accepted a stock option as his sole compensation plan. Chief medical officer Johnson A. Bankole also just acquired over 3,000 shares, perhaps as part of his own compensation plan. If AD04 succeeds in clinical trials, it could be a very profitable drug.
NASDAQ:ADILLong
by ChristopherCarrollSmith
established a Scientific Advisory Board (SAB) and has appointed Adial Pharmaceuticals, Inc. today announced that it has established a Scientific Advisory Board (SAB) and has appointed Dr. Giovanni Addolorato, a leading global expert in the field of alcohol use disorder (AUD), as its first member and Chairperson. The SAB will help to guide the Company’s strategy and advance AD04, its lead therapeutic agent for AUD, with Phase 3 trials expected to commence in the first half of 2019. globenewswire.com seekingalpha.com
NASDAQ:ADILEducation
by AlenCiken